| abstract |
The present invention is based on the finding that, when a multispecific antibody, said multispecific antibody comprising (1) a cancer-specific antigen-binding domain, (2) a CD3-binding domain and (3) a domain having an Fc region in which the binding activity to Fcγ receptor is lowered, is used in combination with an agonist antibody against tumor necrosis factor (TNF) receptor superfamily, side effects such as hepatic disorders observed when the aforesaid agonist antibody is prescribed alone can be reduced and an effective therapeutic effect can be exerted. |